Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Baxter
Moodys
Cerilliant
Accenture
Farmers Insurance
QuintilesIMS
Mallinckrodt
Argus Health

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,736,670

« Back to Dashboard

Summary for Patent: 7,736,670
Title:Method of making particles for use in a pharmaceutical composition
Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.
Inventor(s): Staniforth; John Nicholas (Bath, GB), Green; Matthew Michael James (Surrey, GB), Morton; David Alexander Vodden (Bath, GB)
Assignee: Vectura Limited (Chippenham Wiltshire, GB)
Application Number:10/433,072
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 7,736,670

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sunovion Pharms Inc SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sunovion Pharms Inc UTIBRON glycopyrrolate ; indacaterol maleate POWDER;INHALATION 207930-001 Oct 29, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,736,670

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0029261.5Nov 30, 2000
United Kingdom0030946.8Dec 19, 2000
PCT/GB01/01606Apr 9, 2001
United Kingdom0124010.0Oct 5, 2001
PCT Information
PCT FiledNovember 30, 2001PCT Application Number:PCT/GB01/05315
PCT Publication Date:June 06, 2002PCT Publication Number: WO02/43701

Non-Orange Book US Patents Family Members for Patent 7,736,670

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,101,160 Formulations for use in inhaler devices ➤ Sign Up
8,029,768 Treatment of respiratory diseases ➤ Sign Up
7,229,607 Treatment of respiratory disease ➤ Sign Up
8,932,635 Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Harvard Business School
QuintilesIMS
Cantor Fitzgerald
Fish and Richardson
US Army
Daiichi Sankyo
Moodys
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.